The stock of Horizon Pharma PLC (NASDAQ:HZNP) is a huge mover today! About 5.32 million shares traded hands or 84.08% up from the average. Horizon Pharma PLC (NASDAQ:HZNP) has risen 19.02% since March 8, 2016 and is uptrending. It has outperformed by 9.71% the S&P500.
The move comes after 7 months negative chart setup for the $3.11 billion company. It was reported on Oct, 11 by Barchart.com. We have $17.16 PT which if reached, will make NASDAQ:HZNP worth $186.60M less.
Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to report earnings on November, 4. They expect $0.67 earnings per share, up 13.56% or $0.08 from last year’s $0.59 per share. HZNP’s profit will be $114.11M for 6.81 P/E if the $0.67 EPS becomes a reality. After $0.42 actual earnings per share reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts 59.52% EPS growth.
Horizon Pharma PLC (NASDAQ:HZNP) Ratings Coverage
Out of 9 analysts covering Horizon Pharma (NASDAQ:HZNP), 5 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 56% are positive. Horizon Pharma has been the topic of 18 analyst reports since September 9, 2015 according to StockzIntelligence Inc. The stock of Horizon Pharma PLC (NASDAQ:HZNP) earned “Buy” rating by Mizuho on Tuesday, May 3. Mizuho initiated Horizon Pharma PLC (NASDAQ:HZNP) on Friday, October 9 with “Buy” rating. The stock has “Outperform” rating given by BMO Capital Markets on Wednesday, June 29. Goldman Sachs initiated Horizon Pharma PLC (NASDAQ:HZNP) rating on Monday, June 6. Goldman Sachs has “Buy” rating and $24 price target. Morgan Stanley reinitiated it with “Underweight” rating and $23.0 target price in Thursday, December 3 report. The company was reinitiated on Wednesday, January 6 by Citigroup. The rating was initiated by Jefferies with “Buy” on Tuesday, January 19. Mizuho maintained the shares of HZNP in a report on Tuesday, November 10 with “Buy” rating. Brean Capital downgraded the shares of HZNP in a report on Tuesday, September 22 to “Hold” rating. On Friday, September 16 the stock rating was downgraded by Cowen & Co to “Market Perform”.
According to Zacks Investment Research, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNEÂ® (interferon gamma-1b), DUEXISÂ® (ibuprofen/famotidine), PENNSAIDÂ® (diclofenac sodium topical solution) 2% w/w, RAYOSÂ® (prednisone) delayed-release tablets and VIMOVOÂ® (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment increased to 1.21 in 2016 Q2. Its up 0.21, from 1 in 2016Q1. The ratio increased, as 46 funds sold all Horizon Pharma PLC shares owned while 45 reduced positions. 38 funds bought stakes while 72 increased positions. They now own 135.34 million shares or 2.87% less from 139.33 million shares in 2016Q1.
Geode Capital Ltd Limited Liability Company has 1.10M shares for 0.01% of their US portfolio. Acadian Asset Management Ltd Liability Corporation accumulated 624 shares or 0% of the stock. Moreover, Systematic Fincl Mgmt Limited Partnership has 0.05% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 203,910 shares. Emerald Advisers Inc Pa last reported 204,797 shares in the company. Moreover, Qcm Cayman Ltd has 0.18% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 25,502 shares. Tower Research Ltd Liability (Trc), a New York-based fund reported 1,095 shares. Cubist Systematic Strategies Limited Liability Corp holds 0.07% or 76,420 shares in its portfolio. Bank Of Montreal Can holds 0.01% of its portfolio in Horizon Pharma PLC (NASDAQ:HZNP) for 618,861 shares. Quantitative Investment Mngmt Ltd Liability Corp accumulated 30,500 shares or 0.02% of the stock. The France-based Exane Derivatives has invested 0% in Horizon Pharma PLC (NASDAQ:HZNP). Sg Americas Securities Limited Liability Corporation, a New York-based fund reported 7,078 shares. The New York-based Broadfin Capital has invested 10.99% in Horizon Pharma PLC (NASDAQ:HZNP). Everpoint Asset Ltd Liability Co last reported 1.80 million shares in the company. Moreover, Ameritas Invest Prns has 0.01% invested in Horizon Pharma PLC (NASDAQ:HZNP) for 12,572 shares. Spot Trading Lc, a Illinois-based fund reported 17,651 shares.
Insider Transactions: Since June 15, 2016, the stock had 0 insider buys, and 2 selling transactions for $500,280 net activity. The insider Nohria Virinder sold $442,280. 2,900 Horizon Pharma PLC (NASDAQ:HZNP) shares with value of $58,000 were sold by SHERMAN JEFFREY W.
More important recent Horizon Pharma PLC (NASDAQ:HZNP) news were published by: Schaeffersresearch.com which released: “Hard-Hit Horizon Pharma PLC (HZNP) Mobbed by Bearish Options Bettors” on October 11, 2016, also Streetinsider.com published article titled: “Horizon Pharma plc (HZNP) to Acquire Raptor Pharmaceutical (RPTP) for $800M”, Moodys.com published: “Moody’s: Horizon’s Raptor acquisition credit negative” on September 12, 2016. More interesting news about Horizon Pharma PLC (NASDAQ:HZNP) was released by: Seekingalpha.com and their article: “Horizon Pharma: Another Core Plus Biotech Worth Buying” with publication date: September 28, 2016.
HZNP Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, incorporated on December 20, 2011, is a biopharmaceutical company. The Firm is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. The Firm markets approximately nine medicines through its orphan, primary care and rheumatology business units. The Company’s segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. The Company’s marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Firm also developed DUEXIS and RAYOS, known as LODOTRA.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.